The health and budget impact of sodium-glucose co-transporter-2 inhibitors (SGLT2is) in The Netherlands

References

• Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and the Environment]. Diabetes mellitus | Volksgezondheid en Zorg [Diabetes mellitus | Public Health and Care] [Internet]. [cited 2022 Jun 28]. [Dutch]. Available from: https://www.vzinfo.nl/diabetes-mellitus
   Google Scholar
• Dal Canto E, Ceriello A, Rydén L, et al. Diabetes as a cardiovascular risk factor: an overview of global trends of macro and micro vascular complications. Eur J Prev Cardiol. 2019;26(2_suppl):25–32.
   PubMed Web of Science ®Google Scholar
• Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and the Environment]. Levensverwachting mensen met diabetes aanzienlijk lager [Internet]. 2021 [cited 2022 Jun 28]. [Dutch]. Available from: https://www.rivm.nl/nieuws/levensverwachting-mensen-met-diabetes-aanzienlijk-lager
   Google Scholar
• Barents ESE, Bilo HJG, Bouma M, et al. Diabetes mellitus type 2 | NHG-Richtlijnen [Diabetes mellitus type 2 | Dutch College of General Practitioners Guidelines] [Internet]. 2023 [cited 2022 Jun 26]. [Dutch]. Available from: https://richtlijnen.nhg.org/standaarden/diabetes-mellitus-type-2
   Google Scholar
• Yang Q, Tong X, Schieb L, et al. Vital signs: recent trends in stroke death rates – United States, 2000–2015. MMWR Morb Mortal Wkly Rep. 2017;66(35):933–939.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
   PubMed Web of Science ®Google Scholar
• Heintjes EM, Houben E, Beekman-Hendriks WL, et al. Trends in mortality, cardiovascular complications, and risk factors in type 2 diabetes. Neth J Med. 2019;77(9):317–329.
   PubMed Web of Science ®Google Scholar
• Hart HE, Rutten GE, Bontje KN, et al. Overtreatment of older patients with type 2 diabetes mellitus in primary care. Diabetes Obes Metab. 2018;20(4):1066–1069.
   PubMed Web of Science ®Google Scholar
• Hart HE, Ditzel K, Rutten GE, et al. De-Intensification of blood glucose lowering medication in people identified as being over-treated: a mixed methods study. Patient Prefer Adherence. 2019;13:1775–1783.
   PubMed Web of Science ®Google Scholar
• Van Der Meer V, Wielders HPM, Grootendorst DC, et al. Chronic kidney disease in patients with diabetes mellitus type 2 or hypertension in general practice. Br J Gen Pract. 2010;60(581):884–890.
   PubMed Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39.
   PubMed Web of Science ®Google Scholar
• Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021;372:1–14.
   Google Scholar
• McGuire DK, Shih WJ, Cosentino F, et al. Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis. JAMA Cardiol. 2021;6(2):148–158.
   PubMed Web of Science ®Google Scholar
• Federatie Medisch Specialisten [Federation Medical Specialists].Medicamenteuze behandeling zeerhoogrisicopatiënten DM2 - Richtlijn - Richtlijnendatabase [Drug treatment of very-high-risk type 2 diabetes patients - Guideline - Guideline Database] [Internet]. [cited 2022 May 12]. [Dutch]. Available from: https://richtlijnendatabase.nl/richtlijn/medicamenteuze_behandeling_zeerhoogrisico_patienten_dm2/startpagina_-_farmacotherapie_bij_zeerhoogrisicopati_nten_met_diabetes_mellitus_type_2_dm2.html
   Google Scholar
• Zorginstituut Nederland [National Health Care Institute]. Databank Genees- en hulpmiddelen Informatie Project [Database Medicines and Medical Devices Information Project] [Internet]. [cited 2022 May 12]. [Dutch]. Available from: https://www.gipdatabank.nl
   Google Scholar
• Vanhommerig, J. Jaarcijfers aandoeningen - Huisartsenregistraties. [Annual figures diseases - General Practitioner Registrations] [cited 2022 Jul 30]. [Dutch]. Available from: https://www.nivel.nl/nl/nivel-zorgregistraties-eerste-lijn/jaarcijfers-aandoeningen-huisartsenregistraties
   Google Scholar
• Rijksinstituut voor Volksgezondheid en Milieu [National Institute for Public Health and the Environment]. Diabetes mellitus | Leeftijd en geslacht | Volksgezondheid en Zorg [Diabetes mellitus | Age and gender | Public Health and Care] [Internet]. [cited 2022 Jun 28]. [Dutch]. Available from: https://www.vzinfo.nl/diabetes-mellitus/leeftijd-en-geslacht
   Google Scholar
• Centraal Bureau voor de Statistiek [Statistics Netherlands]. Population development. [Internet]. [cited 2022 Jul 30]. Available from: https://www.cbs.nl/en-gb/series/population-development
   Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, DECLARE–TIMI 58 Investigators, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357.
   PubMed Web of Science ®Google Scholar
• Postmus D, Abdul Pari AA, Jaarsma T, et al. A trial-based economic evaluation of 2 nurse-led disease management programs in heart failure. Am Heart J. Mosby, Inc. 2011;162(6):1096–1104.
   PubMed Web of Science ®Google Scholar
• Alva ML, Gray A, Mihaylova B, et al. The impact of diabetes-related complications on healthcare costs: new results from the UKPDS (UKPDS 84). Diabet Med. 2015;32(4):459–466.
   PubMed Web of Science ®Google Scholar
• Soekhlal RR, Burgers LT, Redekop WK, et al. Treatment costs of acute myocardial infarction in The Netherlands. Netherlands Hear J. 2013;21(5):230–235.
   PubMed Web of Science ®Google Scholar
• Buisman LR, Tan SS, Koudstaal PJ, et al. Hospital costs of ischemic stroke and transient ischemic attack in The Netherlands. Value Heal. 2014;17(7):A485.
   PubMed Web of Science ®Google Scholar
• Boersma C, Gansevoort RT, Pechlivanoglou P, et al. Screen-and-treat strategies for albuminuria to prevent cardiovascular and renal disease: cost-effectiveness of nationwide and targeted interventions based on analysis of cohort data from The Netherlands. Clin Ther Excerpta Medica Inc. 2010;32(6):1103–1121.
   Google Scholar
• Mazairac AHA, Blankestijn PJ, Grooteman MPC, et al. The cost-utility of haemodiafiltration versus haemodialysis in the convective transport study. Nephrol Dial Transplant. 2013;28(7):1865–1873.
   PubMed Web of Science ®Google Scholar
• Niessen LW, Dijkstra R, Hutubessy R, et al. Lifetime health effects and costs of diabetes treatment. Neth J Med. 2003;61(11):355–364.
   PubMed Web of Science ®Google Scholar
• Meerding WJ, Mulder S, Van Beeck EF. Incidence and costs of injuries in The Netherlands. Eur J Public Health. 2006;16(3):271–277.
   Web of Science ®Google Scholar
• Dhatariya KK, Parsekar K, Skedgel C, et al. The cost of treating diabetic ketoacidosis in an adolescent population in the UK: a national survey of hospital resource use. Diabet Med. 2019;36(8):982–987.
   PubMed Web of Science ®Google Scholar
• Hunt B, Glah D, van der Vliet M. Modeling the Long-Term Cost-Effectiveness of IDegLira in patients with type 2 diabetes who are failing to meet glycemic targets on basal insulin alone in The Netherlands. Diabetes Ther. 2017;8(4):753–765.
   PubMed Web of Science ®Google Scholar
• Z-index BV. Z-index database. [cited 2022 Jun 18]. [Dutch]. Available from: https://www.z-index.nl
   Google Scholar
• Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis – principles of good practice: report of the ISPOR 2012 budget impact analysis good practice II task force. Value Heal. 2014;17(1):5–14.
   PubMed Web of Science ®Google Scholar
• Sullivan PW, Ghushchyan VH. EQ-5D scores for diabetes-related comorbidities. Value Heal. 2016;19(8):1002–1008.
   PubMed Web of Science ®Google Scholar
• Peasgood T, Brennan A, Mansell P, et al. The impact of diabetes-related complications on preference-based measures of health-related quality of life in adults with type I diabetes. Med Decis Mak. 2016;36(8):1020–1033.
   PubMed Web of Science ®Google Scholar
• Okkonen M, Havulinna AS, Ukkola O, et al. Risk factors for major adverse cardiovascular events after the first acute coronary syndrome. Ann Med. 2021;53(1):817–823.
   PubMed Web of Science ®Google Scholar
• Young JB, Gauthier-Loiselle M, Bailey RA, et al. Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. Cardiovasc Diabetol. BioMed Central. 2018;17(1):1–13.
   PubMedGoogle Scholar
• Odutayo A, Wong CX, Farkouh M, et al. AKI and long-term risk for cardiovascular events and mortality. J Am Soc Nephrol. 2017;28(1):377–387.
   PubMed Web of Science ®Google Scholar
• Rahamimov R, Van Dijk TY, Molcho M, et al. Acute kidney injury and long-term risk for cardiovascular events in patients after kidney transplantation. Kidney Blood Press Res. 2019;44(5):1149–1157.
   PubMed Web of Science ®Google Scholar